Skip to content

Erector Spinae Plane Block with Different Volumes of Ropivacaine for Postoperative Pain Control in Patients Undergoing Laparoscopic nephrectomy: a double blinded, prospective, and randomized trial

Erector Spinae Plane Block with Different Volumes of Ropivacaine for Postoperative Pain Control in Patients Undergoing Laparoscopic nephrectomy: a double blinded, prospective, and randomized trial

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064685
Enrollment
Unknown
Registered
2022-10-14
Start date
2022-10-17
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic nephrectomy

Interventions

High volume group:0.5% ropivacaine 40 ml
Low volume group :0.5% ropivacaine 20 ml

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 70 years, ASA I-II, BW 50-90kg; 2. Scheduled for laparoscopic total or partial nephrectomy; 3. Agreed to sign up consent of inform preoperatively.

Exclusion criteria

Exclusion criteria: 1. With chronic pain and is dependent on opioid drugs or and kind of analgesic (more than 3 months); 2. With renal region pain; 3. With peripheral tissue invasion, lymph node metastasis and need to receive renal artery embolism; 4. Complicated with sever dementia, language barrier or communication disorder due to end-stage diseases; 5. Allergic to ultrasonic coupling agent and local anesthetic drug; 6. Not profitable for neural block due to local puncture site infection and coagulation disorder; 7. Planned to admit to ICU; 8. Not suitable for the trial by attending doctor or researcher.

Design outcomes

Primary

MeasureTime frame
total consumption of sufentanil in 48h;Visual analog scale, VAS;

Secondary

MeasureTime frame
First time to use PCA;Times and dosage of supplementation of sufentanil;Satisfaction of analgesic effect;Incidence of adverse reactions;Sensory block range;

Countries

China

Contacts

Public ContactYu Zhuoying

Peking University Third Hospital

yingyiqing@126.com+86 13641002503

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026